Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study

BACKGROUND: Concurrent programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors with sequential chemoradiotherapy (SCRT) have been reported in only a limited number of studies involving patients with unresectable stage III non-small-cell lung cancer (NSCLC). A retrospective study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Shi, Cong, Xiaofeng, Zheng, Dan, Chen, Chen, Liu, Zengguang, Gao, Jie, Zhang, Huimin, Zhang, Youhao, Liu, Ziling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157220/
https://www.ncbi.nlm.nih.gov/pubmed/37152047
http://dx.doi.org/10.3389/fonc.2023.1129989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157220/
https://www.ncbi.nlm.nih.gov/pubmed/37152047
http://dx.doi.org/10.3389/fonc.2023.1129989

Ejemplares similares